Effect of Tetrabenazine on Stroop Interference in HD

Huntington Disease Clinical Trial

Official title:

Effect of Tetrabenazine on Stroop Interference in Huntington Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01834911
• Other study ID #: L-10,830
• Status: Completed
• Phase: Phase 4
• First received: April 15, 2013
• Last updated: March 29, 2018
• Start date: March 2013
• Est. completion date: January 1, 2018

Study information

• Verified date: March 2018
• Source: New York Medical College
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: January 1, 2018
• Est. primary completion date: January 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Established diagnosis of Huntington disease by movement disorders expert

• Patients currently taking tetrabenazine.

• Patients should not have taken dopamine receptor blocking medication for at least three days

Exclusion Criteria:

Related Conditions & MeSH terms

• Huntington Disease

Intervention

Drug:
• Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.

Locations

Country	Name	City	State
United States	Terence Cardinal Cooke Health Care Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York Medical College

Country where clinical trial is conducted

United States, 

References & Publications (1)

Fekete R, Davidson A, Ondo WG, Cohen HS. Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord. 2012 Aug;18(7):896-8. doi: 10.1016/j.parkreldis.2012.04.029. Epub 2012 May 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Stroop Interference Score	Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.	6 hours